These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31190276)

  • 1. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.
    Waller CF; Vynnychenko I; Bondarenko I; Shparyk Y; Hodge JP; Freeman A; Huber B; Lieberman R; Shelton MJ; Dave H
    Clin Lung Cancer; 2015 Mar; 16(2):92-9. PubMed ID: 25458558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
    Langer CJ; McAleer CA; Bonjo CA; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols RF
    Eur J Cancer; 2000 Jan; 36(2):183-93. PubMed ID: 10741276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Mok TS; Geater SL; Iannotti N; Thongprasert S; Spira A; Smith D; Lee V; Lim WT; Reyderman L; Wang B; Gopalakrishna P; Garzon F; Xu L; Reynolds C
    Ann Oncol; 2014 Aug; 25(8):1578-84. PubMed ID: 24827127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
    Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
    Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
    Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
    Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
    Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
    Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
    Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
    Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer.
    Tournoux-Facon C; Robinet G; Pinel MC; Ferre P; Tourani JM
    Am J Clin Oncol; 2012 Aug; 35(4):378-85. PubMed ID: 22814308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    Yonemori K; Shimomura A; Yasojima H; Masuda N; Aogi K; Takahashi M; Naito Y; Shimizu S; Nakamura R; Hashimoto J; Yamamoto H; Hirakawa A; Michimae H; Hamada A; Yoshida T; Sukigara T; Tamura K; Fujiwara Y
    Eur J Cancer; 2019 Mar; 109():84-91. PubMed ID: 30703739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
    Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
    Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.